Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [4] - The company's lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury recovery [4] - Addex has a partnership with Indivior for a GABAB PAM drug candidate aimed at substance use disorders and is advancing its own GABAB PAM program for chronic cough [4] - The company holds a 20% equity interest in Neurosterix LLC, which is developing allosteric modulator programs for various neurological conditions [4] Recent Developments - Dr. Robert Lütjens, Head of Discovery - Biology, will present a corporate update and discuss recent advances from Addex's CNS pipeline at the Swiss Equities Baader Conference [2][3] - The presentation is scheduled for January 10, 2025, at 11:40 CET in Bad Ragaz, Switzerland [3] Stock Information - Addex shares are listed on the SIX Swiss Exchange and NASDAQ Capital Market under the ticker symbol "ADXN" [4]
Addex to Present at the 2025 Swiss Equities Baader Conference